Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?

S. Matthijs Boekholdt; Robbert J. de Winter; John J. P. Kastelein

doi:https://doi.org/10.1161/CIRCULATIONAHA.108.795195

Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?

S. Matthijs Boekholdt, Robbert J. de Winter, John J. P. Kastelein

Research output: Contribution to journal › Editorial › Academic › peer-review

13 Citations (Scopus)

Original language	English
Pages (from-to)	1120-1122
Journal	Circulation
Volume	118
Issue number	11
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.108.795195
Publication status	Published - 2008

Access to Document

https://doi.org/10.1161/CIRCULATIONAHA.108.795195

Cite this

@article{9e7219277033488b8368feabe2206732,

title = "Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier?",

author = "Boekholdt, {S. Matthijs} and {de Winter}, {Robbert J.} and Kastelein, {John J. P.}",

year = "2008",

doi = "https://doi.org/10.1161/CIRCULATIONAHA.108.795195",

language = "English",

volume = "118",

pages = "1120--1122",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "11",